0.500
+0.060
(13.64%)
May 22 - Close
OTCMKTS
data delayed by 15 mins -
Disclaimer
Currency in USD
| Range | 0.38 - 0.50 |
| 52 week | 0.22 - 3.99 |
| Open | 0.44 |
| Vol / Avg. | 95,788.00/101,040.00 |
| Mkt cap | 5.49M |
| P/E | - |
| Div/yield | - |
| EPS | -1.13 |
| Shares | 10.99M |
| Beta | 0.63 |
| Inst. own | 2% |
Events
Mar 12, 2013
Q2 2013 PURE Bioscience Earnings Release
|
|
Key stats and ratios
| Q1 (Jan '13) | 2012 | |
| Net profit margin | -693.54% | -1094.83% |
| Operating margin | -688.21% | -1078.08% |
| EBITD margin | - | -1030.66% |
| Return on average assets | -149.32% | -185.09% |
| Return on average equity | -303.51% | -353.83% |
| Employees | 23 | - |
| Carbon Disclosure Rating | - | - |
Address
Website links
External links
Discussion Group - Google Finance
Advertisement
Description
Pure Bioscience, Inc. (PURE) is focused on the discovery, development and commercialization of bioscience products. PURE�s technology platform is based on stabilized ionic silver, and its initial products contain silver dihydrogen citrate (SDC).The Company manufactures and sells SDC-based disinfecting and sanitizing products. PURE also manufactures and sells various SDC-based formulations to manufacturers for use as a raw material in the production of personal care and other products. The Company�s products include PURE Complete System, which includes PURE Hard Surface, PURE Multi-Purpose Cleaner Concentrate and PURE Floor Cleaner Concentrate; Axen 30; Axenohl, and Silverion.
Officers and directors
| Michael L. Krall | Chairman of the Board, President, Chief Executive Officer, Interim Chief Financial Officer | |
| Donna M. Singer | Executive Vice President, Director | |
| Dennis Brovarone | Independent Director | |
| John J. Carbone M.D. | Independent Director | |
| Paul V. Maier | Independent Director | |
| Dave Pfanzelter | Independent Director |